Company intelligence / Profile preview

CG Pharmaceuticals

Orinda, California, United Statescgpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

CG Pharmaceuticals is conducting a Phase 1b/2 clinical trial for ivaltinostat in metastatic pancreatic cancer. The Phase 1b study has been completed with 28 patients across 3 dose levels, showing a manageable safety profile with primarily grade 1-2 adverse events. Phase 2 enrollment is ongoing with completion expected in 2025 and final clinical study report by mid-2026[1][3].

Therapeutic areas: OncologyCardiovascular
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

ivaltinostat

Phase 2

Indications: Metastatic pancreatic ductal adenocarcinoma

Beyond the preview

Go deeper on CG Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG Pharmaceuticals.

Explore the full profile